BEDFORD, Mass., January 22, 2018 – Homology Medicines, Inc., a genetic medicines company, announced today that Chief Scientific Officer Albert Seymour, Ph.D., will participate in a panel on gene editing at the Phacilitate Cell & Gene Therapy World Conference. The panel entitled, “What do we know so far about the efficiency/accuracy/safety of the various gene editing platforms in both in vivo and ex vivo therapeutic applications?” will take place on January 23, 2018 at 4:05 p.m. ET at the Hyatt Regency in Miami.
The Cell & Gene Therapy World Conference is the largest meeting for cell and gene therapy, bringing together industry leaders to explore industry trends, opportunities, disruptions and major shifts on the horizon.
About Homology Medicines, Inc.
Homology Medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The combination of a new multidimensional gene correction platform and a management team that has successfully developed and commercialized therapies for the treatment of rare diseases positions the Company to move beyond the current limitations of gene therapy and gene editing approaches to improve patient care. Homology Medicines has built foundational intellectual property on gene editing and gene therapy using vectors derived from naturally occurring human adeno-associated viruses (AAVs). The Company’s technology is precise, on-target and highly efficient for in vivo editing of genetic mutations. The team and technology create a significant opportunity for Homology to rapidly advance a diverse pipeline of new medicines that address and potentially cure the underlying cause of genetic diseases. For more information, please visit www.homologymedicines.com.